Weight Loss Research · Pembroke Pines, FL

About Retatrutide &
What We Currently Offer

Retatrutide (sometimes called "Reta" or "Reta peptide") is a promising investigational weight-loss medication that activates three hormone receptors simultaneously. The early clinical data is impressive — but it is not yet FDA approved, and CardioMender MD does not currently offer it.

CardioMender MD currently offers tirzepatide (Zepbound/Mounjaro) — an FDA-approved dual-agonist with outstanding clinical results that are comparable to retatrutide. If and when retatrutide receives FDA approval, we will evaluate adding it to our program.

Ask About Tirzepatide See How They Compare

🏆

24–28%

Average Total Body Weight Loss Reported

82%

Patients Achieving >15% Reduction

86%

Reduction in Liver Fat (Early Studies)

3×

Hormone Receptors Activated (GGG)

Physician-Supervised Treatment

Overview

What is Retatrutide?

Retatrutide is an investigational prescription injectable given as a weekly subcutaneous shot. It is not yet FDA approved and is not available through CardioMender MD at this time. The information below is provided for educational purposes, and to help you understand why we recommend tirzepatide as the next best option.

CardioMender MD offers tirzepatide (Zepbound), a dual-agonist that is FDA-approved and has demonstrated exceptional weight-loss results in clinical trials — with average reductions of 15–21% body weight. It shares retatrutide's GLP-1 and GIP mechanisms and is available today under physician supervision.

💉

Once-Weekly Injection

Administered as a subcutaneous shot under the skin, using a dose-escalation approach for better tolerability.

🔬

Triple-Receptor Action

Activates GLP-1, GIP, and glucagon receptors simultaneously — uniquely targeting appetite, insulin, and energy burn.

🩺

Physician-Led Program

Requires medical review of health history and regular follow-ups to ensure safe, structured progress.

The Science

Retatrutide Triple Hormone Receptor Agonist (GGG)

Retatrutide is often called a “triple agonist” because it activates three different hormone receptors that help regulate appetite, blood sugar, and metabolism: GLP-1, GIP, and glucagon.

GLP-1

Glucagon-Like Peptide-1

GLP-1 is a natural “after-meal” hormone. When GLP-1 receptors are activated, the brain gets stronger fullness signals, the stomach empties more slowly (so you stay full longer), and the pancreas releases insulin in a glucose-dependent way (more support when blood sugar is higher). That combination is a big reason GLP-1 medicines tend to reduce appetite.

GIP

Glucose-Dependent Insulinotropic Peptide

GIP is another incretin hormone that also supports insulin release after meals. GIP activation may improve insulin sensitivity (how well your cells respond to insulin), which can help the body handle carbs more smoothly.

Glucagon

Glucagon Receptor

Glucagon is best known for raising blood sugar. Still, it also has effects tied to higher energy use, including supporting “calorie burn at rest” through metabolic pathways in the liver and other tissues. The idea behind pairing glucagon activity with GLP-1/GIP is to boost energy expenditure while GLP-1/GIP help keep appetite and glucose control in check.

01

Triple-Action Mechanism (GLP-1, GIP, and Glucagon)

Retatrutide is designed to act on three hormone receptors involved in appetite, blood sugar regulation, and energy use.

02

Substantial Weight Loss

Higher-dose groups have reported (alternate source) (alternate source 2) average retatrutide weight loss around the mid-20% range over about a year, with longer studies reporting results approaching the high-20% range. (Results vary by dose, time on retatrutide treatment, and individual factors.)

Up to 24–28% total body weight

03

High Success Rate

In a 48-week study, approximately 83% of participants on the highest dose lost at least 15% of their starting body weight — a remarkable clinical benchmark.

82% of patients achieve >15% reduction

04

Increased Energy Expenditure & Fat Metabolism

The glucagon-receptor part of the retatrutide weight loss injection is intended to increase “energy expenditure,” meaning your body may burn more calories at rest and rely more on stored energy.

05

Significant Reduction in Liver Fat

Early studies also suggest large reductions in liver fat on imaging in some people, which is why retatrutide is being explored for metabolic conditions beyond weight.

Up to 86% liver fat reduction

06

Improved Metabolic Markers

Weight loss aside, researchers have reported improvements in several cardiometabolic measures (the kinds of numbers clinicians track for long-term health).

07

Reduced "Food Noise" & Increased Satiety

It may help have fewer intrusive food thoughts and feel full sooner; this aligns with how GLP-1/GIP signaling influences appetite and fullness.

08

Enhanced Muscle Preservation

Any significant weight loss can involve some lean-mass loss, so preserving muscle usually depends on the full plan, which typically includes adequate protein, resistance training, and close medical guidance as weight comes down.

Comparison

Retatrutide vs\. Tirzepatide — What CardioMender Offers

Retatrutide shows slightly higher average weight loss than tirzepatide in early trials, but it is not FDA approved. Tirzepatide (Zepbound) is FDA approved, widely available, and delivers outstanding results — and it is what CardioMender MD currently offers.

Medication	Mechanism	Study Duration	Avg. Weight Loss	Notable Feature
Semaglutide (Wegovy)	GLP-1 agonist	68 weeks	~14.9%	FDA-approved; strong safety profile
Tirzepatide (Zepbound)	GLP-1 + GIP dual agonist	72 weeks	15.0–20.9%	Dual receptor; FDA-approved for obesity
Retatrutide (Reta)	GLP-1 + GIP + Glucagon (triple)	48 weeks	22.8–24.2%	Highest reported weight loss; investigational

Why We Offer Tirzepatide Instead: Tirzepatide (Zepbound/Mounjaro) is FDA approved, has a well-established safety profile, and achieves average weight loss of 15–21% — among the best results of any approved medication. Retatrutide's additional glucagon receptor may offer a modest advantage, but it remains investigational. When FDA approval occurs, we will reassess. Until then, tirzepatide is the most effective, safest option we can offer.

Who Qualifies

Candidates for Tirzepatide at CardioMender

Because CardioMender MD does not currently offer retatrutide (it is not FDA approved), the candidate criteria below describe who qualifies for tirzepatide — the FDA-approved alternative we do offer, with comparable results.

✅ Who Is a Good Candidate

✓
Adults with obesity (BMI 30+) — Often considered when weight is affecting health or daily life.
✓
Overweight with comorbidities (BMI 27+) — Including high blood pressure or high cholesterol tied to medical risk factors.
✓
Patients with weight-related conditions — Sleep apnea, osteoarthritis, and cardiovascular disease may all be impacted by excess weight.
✓
Individuals with metabolic dysfunction — Conditions like NAFLD/MASLD or chronic kidney disease may be part of the discussion.
✓
People who plateaued on Wegovy or Zepbound — Some patients stop losing after early progress and require a plan adjustment.
✓
Those seeking non-surgical bariatric-style results — For people who prefer to avoid surgery and have realistic expectations.
✓
Individuals struggling with "food noise" and cravings — Constant food thoughts or cravings that feel hard to control.

⛔ Exclusions & Contraindications

✕
Type 1 diabetes — Reta-peptide research is focused on obesity and metabolic disease, not insulin replacement.
✕
History of pancreatitis — Many programs avoid incretin-based therapies in patients with prior pancreatitis due to safety concerns.
✕
Personal or family history of medullary thyroid carcinoma (MTC) — A major red flag for this medication class.
✕
Multiple Endocrine Neoplasia type 2 (MEN-2) — Another key exclusion tied to thyroid tumor risk.
✕
Recent significant weight change (>5 kg in 90 days) — A big recent change makes it difficult to assess baseline health and response.
✕
Pregnancy, breastfeeding, or planning to conceive — Generally avoided during these periods for safety reasons.
✕
Major cardiovascular event in the last 3 months — Recent heart attack, stroke, or similar events usually require stabilization first.

Why Choose Us

Why Choose CardioMender for Tirzepatide Treatment?

We do not currently offer retatrutide — it is not yet FDA approved. What we do offer is tirzepatide (Zepbound), an FDA-approved dual-agonist that has delivered some of the strongest weight-loss results of any approved medication. Like retatrutide, it isn't something we hand out after a quick chat. We check your heart health before prescribing, because weight-loss treatment should support your health, not introduce new risks.

A physician monitors your progress with regular follow-ups, reviews side effects, and adjusts your plan when needed. Tirzepatide requires the same level of professional oversight — and at CardioMender MD, that is exactly what you receive.

🫀

Cardiac-First Approach — We review your cardiovascular health before every treatment decision.

🩺

Physician-Only Oversight — A licensed physician manages your entire treatment, not a coordinator.

🥗

Nutrition & Behavior Integration — Medication is paired with lifestyle coaching for sustainable results.

✨

Aesthetic Add-Ons Available — Body contouring and other aesthetic treatments available to complement your journey.

Request a Consultation

Service Areas